SCHEMBL26669816

SCHEMBL26669816

Cc1nccc(N2CCN[C@@H](C)C2)n1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PRKCQ Q04759 3/20 0.48
▸ PRKCD Q05655 1/20 0.48
▸ PIM1 P11309 1/20 0.44
▸ PIM3 Q86V86 1/20 0.44
▸ PIM2 Q9P1W9 1/20 0.44
▸ ACVR1 Q04771 2/20 0.43
▸ NMT1 P30419 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.42
▸ CSNK1E P49674 2/20 0.41
▸ GPBAR1 Q8TDU6 1/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ ZAP70 P43403 3/20 0.41
▸ PRKD1 Q15139 2/20 0.41
▸ PRKD2 Q9BZL6 2/20 0.41
▸ TLR9 Q9NR96 2/20 0.40
▸ TLR8 Q9NR97 2/20 0.40
▸ TLR7 Q9NYK1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL26599759 0.88 HRH4 (0.48) PRKCQPRKCDPIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL26599770 0.88 HRH4 (0.48) PRKCQPRKCDPIM1PIM3PIM2
SCHEMBL27635882 0.84 PRKCQ (0.47) PRKCQPRKCDPIM1PIM3PIM2
SCHEMBL27635881 0.84 PRKCQ (0.47) PRKCQPRKCDPIM1PIM3PIM2
SCHEMBL14258793 0.83 PRKCQ (0.52) PRKCQPRKCDNMT1HRH3GPBAR1
SCHEMBL6976678 0.79 HRH3 (0.65) HRH3
SCHEMBL14186225 0.79 NMT1 (0.49) PRKCQPRKCDPIM1PIM3PIM2
SCHEMBL8271848 0.79 NMT1 (0.49) PRKCQPRKCDPIM1PIM3PIM2
SCHEMBL2244070 0.79 NMT1 (0.49) PRKCQPRKCDPIM1PIM3PIM2
Hydrochloric Acid SCHEMBL6977782 0.78 HRH3 (0.63) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS SREBF1, SREBF2, NR1H3 PRKCQ 715/4885PRKCD 559/4885PIM1 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback